Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 1970427.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In a double-blind placebo-controlled study, we evaluated the effects of clozapine (75 to 250 mg/day, mean 170.8) on dopaminomimetic psychosis and parkinsonian disability. Clozapine prevented deterioration of psychosis during the increase of dopaminomimetics in the 3 patients who completed the study. Worsening of parkinsonism occurred in 3 of the 6 patients. In the dosage used, clozapine's usefulness was limited by its propensity to produce sedation, confusion, and increased parkinsonism.
Medical subject headings
- Clozapine
- Dibenzazepines
- Dopamine Agents
- Parkinson Disease
- Psychoses, Substance-Induced